Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron expected in India in first half of 2027

The Economic Times reports, citing industry sources, that Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron are expected to enter India in the first half of 2027. Officials say both drugs have been submitted to Indian regulators. Doctors quoted by the paper say pills could appeal to people avoiding injections or seeking to maintain weight loss; one cautions that convenience may not solve long-term adherence and that pricing will matter.